Background:
clinical trials are highly selected patients who may not be representative of the majority of patients with a condition. We wanted to explore the effects of beta-blockade on weight change in unselected patients with CHF to see if these findings are generally applicable.
We explored the effects of sympathetic blockade on weight change and mortality in a large cohort of well-characterised patients with CHF.
Methods
Consecutive patients referred between 2000 and February 2016 with suspected HF by either primary or secondary physicians to a community HF clinic, which serves a local population of about 500,000 people, were enrolled. Some patients had no prior diagnosis of HF and were treatment naive, therefore requiring initiation of guideline-recommended therapy; many others had a pre-existing diagnosis of HF and had already been initiated on treatment that might, however, require optimisation.
Because a beta-blocker is recommended only for patients with HF and reduced left ventricular ejection fraction (LVEF), we included only those patients who had signs or symptoms of CHF and LVEF <40% (or at least moderate left ventricular systolic dysfunction by visual inspection if LVEF was not measured). 3 
(Appendix 1)
Only patients who had weight recorded at baseline and at 1 year visit were included. Patients with weight loss of >6% between baseline and 1 year were defined as having cachexia. A higher cut-off than the usual 5% was used to ensure we only included patients with significant weight change, as weight may fluctuate in patients with CHF as a result of changes in fluid status. Indeed, there is also evidence to suggest that a cut-off of 6% weight loss should be used to define the presence cachexia in patients with CHF. 7 Patients with weight gain of ≥5% from baseline were classified as having significant weight gain. 7 For patients who had 3 or more weight measurements recorded between baseline and 1 year visit (N=1361 (92%)), we also determined the variability of body weight by calculating the standard deviation of weight measurements recorded between baseline and 1 year. 8 All patients had a full medical history and physical examination. Ischaemic heart disease (IHD) was defined as any previous medical history of acute coronary syndrome (ACS), percutaneous coronary intervention or coronary artery bypass surgery, or a diagnosis of myocardial ischemia based on invasive or non-invasive diagnostic tests. Cerebrovascular disease (CVD) was defined as any previous history of stroke or transient ischaemic attack (TIA). Peripheral vascular disease (PVD) was defined as a clinical history of the diagnosis.
Blood was taken for standard haematology, biochemistry profile and N-terminal pro B-type natriuretic peptide (NTproBNP). Patients were weighed in their casual wear without shoes.
Body mass index (BMI) was calculated using the formula: BMI = weight in kilograms / (height in meters) squared.
All patients were regularly seen in the HF clinic, usually at baseline, after 4 and 12 months, and then yearly, unless an expedited appointment was requested. HF medications were optimised and diuretic dose adjusted to maintain euvolaemia and dry weight. Weight loss with dietary restriction was not routinely advised for overweight or obese patients, although a healthy diet and regular physical exercise was always recommended.
We classified patients into 4 groups: 1) on beta-blocker therapy at baseline and 1 year; 2) not on beta-blocker therapy at baseline but on beta-blocker therapy at 1 year; 3) on beta-blocker therapy at baseline but not on beta-blocker therapy at 1 year; and 4) not on beta-blocker therapy at either time point. As group 3 had very few patients (N=41 (3%)), we excluded this group from further analysis, although patients in group 3 seem to be sicker than patients in other beta-blocker treatment groups.
We also stratified patients into 3 BMI (kg/m 2 ) categories: 1) underweight/normal (BMI<25.0), 2) overweight (BMI = 25.0-29.9) and 3) obese (BMI ≥ 30.0).
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End points and follow-up
Patients were followed up until 9 th March 2017. The primary endpoint was all-cause mortality. Our hospital is the only one in the region offering acute medical services. With previous consent from patients, we could access all their primary and secondary care records.
Data regarding deaths were collected from the hospital's electronic systems and were entered into a dedicated database, stored on a secure NHS server.
Statistical analysis
Continuous data are expressed as medians with interquartile ranges (IQR) (25 th to 75 th centiles) and categorical data are expressed as N (%). Independent t tests and nonparametric tests were used to compare medians across ordered groups for normally and nonnormally distributed variables, respectively. The chi-squared test was used to compare proportions between groups. Pearson's correlation or Spearman's correlation coefficients were used to assess the relationships between two variables. Log-transformation was applied when the data were very skewed.
Cumulative incidence curves for all-cause mortality were constructed by the Kaplan-Meier method. The relationships between baseline BMI, beta-blocker treatment, degree of weight change and the risk of all-cause mortality were examined using Cox proportional hazards regression models.
All statistical analyses were performed using SPSS 22 (SPSS INc.,Chicago, IL, USA) and
The Stata (14 th Version, StataCorp, TX, USA) statistical computer package. A two-tailed P value of <0.05 was considered significant in all analyses.
The study conformed to the principles outlined in the Declaration of Helsinki and was approved by relevant ethical bodies. All subjects gave their written informed consent for their data to be used for research.
Results

Patient characteristics
The baseline characteristics of the 1480 patients meeting the inclusion criteria are shown in table 1.
Beta-blocker therapy
Of the 3 beta-blocker therapy groups we focused on, patients who did not have beta-blocker therapy at any point were the oldest, most likely to be female, had the most severe symptoms and greatest signs of congestion. They were also the least likely to be on angiotensin converting enzyme inhibitor or angiotensin receptor blockers (ACEi/ARB). Patients who did not have beta-blocker therapy at baseline but had beta-blocker therapy at 1 year had the highest baseline NTproBNP. (Table 1a )
Cachexia and significant weight gain
Cachexia occurred in 13% (N=185) and significant weight gain occurred in 24% (N=363) of patients. (Table 1b) Compared to those with significant weight gain or stable weight, those who developed cachexia were older, had higher BMI, worse symptoms and congestion, higher baseline NTproBNP, lower haemoglobin, worse renal function, were less likely to be on ACEi or mineralocorticoid receptor antagonist (MRA) and had a smaller fall in NTproBNP at 1 year. (Table 1b) Weight change and beta-blocker therapy
The incidence of cachexia was higher in patients who did not have beta-blocker therapy than in patients who had beta-blocker therapy at baseline and 1 year (P<0.001). (Appendix 2a) The incidence of significant weight gain was higher in patients who had beta-blocker therapy either at baseline or initiated between baseline and 1 year than in patients who did not have beta-blocker therapy (P<0.001). (Appendix 2a)
Weight change and baseline BMI
The incidence of cachexia was higher in patients who were obese (BMI ≥ 30 kg/m 2 ) than in patients who were overweight (BMI = 25.0-29.9 kg/m 2 ) or normal/underweight (BMI <25 kg/m 2 ) (P <0.001). (Appendix 2b) The incidence of significant weight gain was lower in obese patients than in patients who were overweight or normal/ underweight (P <0.001).
(Appendix 2b) Univariable and multivariable predictors of mortality are shown in Table 2 . In univariable analysis, increasing BMI, significant weight gain and beta-blocker therapy were associated with a better outcome. In multivariable analysis, the development of cachexia and the absence of beta-blocker therapy were independently associated with increasing all-cause mortality. 
Variability in weight in HF patients
Kaplan
Discussion
We found that amongst patients with CHF due to LVSD, those who were not receiving or were unable to take beta-blockers were more likely to develop cachexia and less likely to have significant weight gain than patients who received beta-blocker therapy. Significant weight gain and beta-blocker therapy were independently associated with improved survival.
Our results are similar to those from the COPERNICUS trial, which studied 2289 patients with HF and left ventricular ejection fraction of <25%. Compared to patients randomised to placebo, those who received carvedilol were 33% less likely to become cachectic (weight loss of >6%) and 37% more likely to have a significant gain in weight (≥5%): these changes were associated with better outcome. 7 It is difficult to dissect the exact causal explanation for these findings. The beneficial effects of beta-adrenergic blockade on cardiac cachexia might be related to the role of the sympathetic activation on the development of cardiac cachexia. 10 Patients with CHF have marked sympathetic activation; in particular cachectic patients have a higher level of circulating noradrenaline than non-cachectic patients with HF. Sympathetic activation might contribute to cachexia by increasing total body energy expenditure 11 and directly exerting a myotoxic effect on skeletal muscle. 12 It also inhibits the secretion of leptin, 13 stimulates release of pro-inflammatory cytokines 14 and the development of insulin resistance, 15 which can all lead to wasting of muscle and adipose cells.
Beta-blockade reduces total body resting energy expenditure and prevents catecholamineinduced myotoxicity. 16 Beta-blockade might also prevent weight loss by improving fatigue and exercise tolerance, 17 perhaps in association with improved appetite. Inhibition of the renin-angiotensin system in patients with heart failure by angiotensin converting enzyme inhibitors and angiotensin receptor blockers also reduces the likelihood of weight loss, 18, 19 suggesting that there is a strong relation between neurohormonal activation and weight loss.
Although obesity is a risk factor for developing heart failure, once HF develops, a higher BMI is associated with better survival, a phenomenon sometimes called the obesity paradox.
Current guidelines do not recommend weight loss in patients with CHF and BMI<35. 20, 21 We have found that incident cachexia is more common in obese patients than normal weight patients. It is important to acknowledge that weight loss in obese patients carries a poor prognosis, even though weight loss might result in a body mass index still in the normal range. 22 Patients who are a normal weight/BMI and who develop heart failure have less weight to lose than those who are obese. However, the prognosis seems to be related to proportional loss of weight, and so their prognosis is better than in obese patients who lose weight. Weight loss in an obese patient should therefore trigger the same if not more concern as weight loss in a patient with normal weight.
Weight loss is a poor prognostic sign and should alert the physician that the patient is deteriorating. Betablockers attenuate weight loss, emphasising the importance of their use in all patients with HeFREF as soon as possible after the diagnosis is made.
Limitations:
Our findings should be interpreted with caution for several reasons.
Firstly, the definition of cachexia is arbitrary, and might not be appropriate in all patients with CHF. Changes in weight following treatment, including beta-blockers, ACEi and diuretics, might be related to changes in fluid status rather than loss of muscle or fat mass.
However, it would be highly unlikely that many ambulatory patients with CHF have substantial (>5% of body weight) fluid accumulation; we also found that weight loss between baseline and 1 year was correlated with worsening rather than improved oedema status.
Secondly, patients were enrolled between 2000 and 2016, and clinical practice has substantially changed over this period. We did not look at changes in the incidence of cachexia over time in our study. It is possible that the prevalence of cachexia is increasing as patients age and are at lower risk of sudden death compared to around 20 years ago. 23 Thirdly, we cannot ascertain whether weight loss was intentional or unintentional and we did not collect information on whether weight loss occurred in the presence of concomitant comorbities, such as cancer, which would have contributed to incident cachexia, and worse outcome, at least in some.
Fourthly, we only analysed weight change during baseline and 1 year follow-up, and thus those who died within a year, or did not attend 1-year follow-up visit, were not included in the analysis. Moreover, we have no data on weight changes from 1 year to time of event.
Fifthly, the effect of beta-blockade on cachexia might be confounded by other factors, such as changes in other anti-HF medications or the use of cardiac resynchronisation therapy, both of which prevent weight loss in patients.
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In addition, we found that patients without beta-blockers at any time were the oldest and sickest; they also had the worst prognosis. It would be interesting to know whether survival in this group is related to the duration since heart failure diagnosis. We included patients from their first visit to the heart failure service and data from before presentation were not available. However, we have no reason to suspect that this particular group had heart failure for longer than other patients.
Finally, this is a single observational study conducted in the UK; external validation of our results from other countries with different healthcare and social systems is needed.
Conclusion:
Around 13% of patients with CHF due to LVSD develop cachexia during one year follow up.
Those who are not treated with beta-blockers are at higher risk of developing cachexia and have the worst survival. The findings support the role of sympathetic antagonism in the prevention of cachexia. 
Legends
Tables: Table 1a . Baseline characteristics of patients with CHF according to beta-blocker treatment groups. (10) 107 (29) 211 (58) 49 (13) 37 (22) 91 (55) 38 (23) 7 (17) 29 (71) 5 (12) 363 (25) 932 (63) 185 (12) 72 (8) 26 (7) 17 (10) 2 (5) 117 (8) 0 0.55 PVD, n (%) 64 (7) 36 (10) 9 (5) 4 (10) 113 (8) 0 0.23
Clinical examination
Baseline visit
Lung crepitation, n (%)
106 (12) 83 (23) 45 (27) 10 (24) 244 (17) (5) 29 (8) 12 (7) 2 (5) 84 (6) 0 0.09
41 (5) 19 (5) 12 (7) 2 (5) 74 (5) (5) 23 (3) 328 (89) 26 (7) 13 (4) 149 (90) 12 (7) 5 (3) 38 (93) 2 (5) 1 (2) 1350 (91) 88 (6) HF= heart failure, LVEF= left ventricular ejection fraction, NTProBNP= N-terminal Pro Brain Natriuretic Peptide, HeFREF= heart failure with reduced ejection fraction, HeFNEF= heart failure with normal ejection fraction, BP= blood pressure, HR = heart rate, 1y= 1 year, BMI= body mass index, SD= standard deviation, IHD= ischaemic heart disease, CVA= cerebral vascular accident, PVD= peripheral vascular disease, JVP= jugular venous pressure, NYHA= New York Heart Association class, Hb= haemoglobin, K+= potassium, Na= sodium, ACEi= angiotensin converting enzyme inhibitor, ARB= angiotensin receptor blocker, MRA= mineralocorticoid receptor antagonist, BL= baseline, BB= Beta-blocker *P-value for trend except when there are > 2 categories (e.g. NYHA class ) (17) 32 (17) 755 (81) 125 (13) 52 (6) 299 (82) 49 (14) 26 ( (7) 8 (4) 853 (91) 56 (6) 23 (3) 332 (91) 20 (6) 11 (3 Peptide, HeFREF= heart failure with reduced ejection fraction, HeFNEF= heart failure with normal ejection fraction, BP= blood pressure, HR = heart rate, 1y= 1 year, BMI= body mass index, SD= standard deviation, IHD= ischaemic heart disease, CVA= cerebral vascular accident, PVD= peripheral vascular disease, JVP= jugular venous pressure, NYHA= New York Heart Association class, Hb= haemoglobin, K+= potassium, Na= sodium, ACEi= angiotensin converting enzyme inhibitor, BL= baseline, BB= Betablocker *P-value for trend except when there are > 2 categories (e.g. NYHA class) 
Highlights
 Around 13% of patients with CHF due to LVSD develop cachexia during one year follow up.  Those who are not treated with beta-blockers are at higher risk of developing cachexia and have the worst survival.  The findings support the role of sympathetic antagonism in the prevention of cachexia. 
